Navigation Links
Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
Date:12/18/2007

wo significant safety concerns: potential for serious liver injury (including rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) and high potential for major birth defects. Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. Pregnancy must be excluded and prevented by two forms of birth control; monthly pregnancy tests should be obtained. Because of these risks, Tracleer is only supplied through a controlled distribution system, the Tracleer Access Program (T.A.P.(R))

About Ventavis(R)

Ventavis(R) (iloprost) is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins -- naturally occurring molecules that cause blood vessels to dilate. Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with New York Heart Association (NYHA) Functional Class III or IV. In controlled trials, Ventavis improved a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration.

In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

About Actelion Pharmaceuticals

Actelion Pharmaceuticals has pioneered research and development in the pulmonary arterial hypertension (PAH) disease area. More than 40,000 PAH patients have been prescribed Actelion's product Tracleer, an orally available dual endothelin receptor ant
'/>"/>

SOURCE Actelion Pharmaceuticals US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
2. International Survey Shows People Over Forty Ignore Risk of Blindness
3. 2007 Global Survey Identifies Characteristics of Supply Chain Leaders
4. Survey Sees Mass. CEOs as Bullish on Own Businesses
5. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
6. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
7. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Cranford, NJ (PRWEB) October 22, 2014 ... technologies and services – has been working with a ... Health and New Haven Farms Community Farming Collaborative to ... iPad-based ePRO solution. The study, which started in ... Wellness program that provides participants weekly exposure to and ...
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... Received a New Patent for a Non-statistical Approach... -- ST. PAUL, Minnesota and PARIS, October 6, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we ...
... anklets are treasures but these gemstones inside the body ... researchers are building implants made of diamond and flexible ... changes in the brain of patients suffering from neural ... the paralyzed. The work of Heidi Martin, a ...
... sensors, are widely used as a navigational tool in ... of a vehicle on three axes to evaluate its ... Aviv University,s School of Physical Engineering is now scaling ... medical equipment and more futuristic technologies. Working in ...
Cached Biology Technology:INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model 2INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model 3INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model 4INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model 5INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model 6INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model 7Gem of an idea: A flexible diamond-studded electrode implanted for life 2Gem of an idea: A flexible diamond-studded electrode implanted for life 3A tracking device that fits on the head of a pin 2
(Date:10/14/2014)... A new study published in Cancer Research ... liver and colon cancers—can promote the development of skin ... proliferation and survival of sun-damaged skin cells. , Previously ... seven proteins called sirtuins that help regulate genomic stability ... aging. SIRT6 helps repair DNA damage, which can lead ...
(Date:10/14/2014)... planet,s leading questions is how to produce enough food ... The Food and Agriculture Organization of the United Nations ... next 40 years to feed a growing global population, ... rise in food production. Plants—grains, cereals, fruits, vegetables, ... Current research must tap into our knowledge of ...
(Date:10/14/2014)... 14, 2014 – Scientists from The Scripps Research Institute ... Institutes of Health (NIH) to lead an investigation of ... disease in Africa. The study aims to understand how ... die, while others survive the inflection. , "The ... mechanism of how Lassa fever virus causes disease and ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... October 23, 2008 -- Are green schools acoustically sound? How ... manatees from getting hit by ships? What secrets will comparing ... hidden cars in forests and buried mines underwater? What is ... brain deal with sound? These are a few of ...
... explains the impact,of negative campaigning tactics and the ... conscientiousness are best predictors of,candidate preference and other ... SP Labs - the,research arm of Signal Patterns, ... connect people in meaningful ways -,today released its ...
... on low calorie diets. But now researchers at Washington University ... can extend the life spans of roundworms even when the ... that blocks their sense of smell. Three years ago, ... found that a class of anticonvulsant medications made the roundworm ...
Cached Biology News:156th Acoustical Society of America Meeting, Nov. 10-14, 2008 in Miami 2156th Acoustical Society of America Meeting, Nov. 10-14, 2008 in Miami 3156th Acoustical Society of America Meeting, Nov. 10-14, 2008 in Miami 4156th Acoustical Society of America Meeting, Nov. 10-14, 2008 in Miami 5156th Acoustical Society of America Meeting, Nov. 10-14, 2008 in Miami 6156th Acoustical Society of America Meeting, Nov. 10-14, 2008 in Miami 7New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 2New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 3New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 4Deprived of a sense of smell, worms live longer 2
... The Agilent One-Color RNA Spike-In Kit ... specifically anneal only to complementary control probes ... cross-hybridization. The spike-ins serve as a positive ... NOTE: This kit is a ...
... spatulas have been designed to save time ... those interested in eliminating the recycling and ... is individually packaged, RNase/DNase free, non-pyrogenic and ... new product number, created to easily match ...
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... CHEMICONs Alkaline Phosphatase Detection Kit (Catalog ... tool for the phenotypic assessment of ES ... activity. Available separately from CHEMICON are ... and TRA-2-54 (Catalog Number MAB4354), which permit ...
Biology Products: